Gilbert syndrome
Enzyme or protein defect
UGT1A1 (reduced activity)
Accumulates or becomes deficient
Unconjugated bilirubin
Key features
Mild intermittent jaundice with fasting, illness or stress; otherwise benign
Management
Reassurance
Not clinical guidance. Written from standard clinical biochemistry, not from the uploaded documents, and marked unreviewed. Teaching-level reference for study and database seeding only. It must not be used to manage a patient.
Recent literature
Europe PMC · from cache · sorted by publication date
-
1
Beyond Gilbert syndrome: exploring the heterozygous UGT1A1 c.41_40dup variant as a potential modifier of bile composition associated with a cholangiopathic phenotype in adults with unexplained chronic cholestasis.
Federico A, Romeo M, Di Nardo F, Napolitano C, De Gregorio A, Basile C, Senese G, Dallio M. · 2026-07-21
unreviewed -
2
Analytical validation of a high-resolution melting assay for UGT1A1 TATA-box polymorphisms.
Gambarino S, Clemente A, Pau A, Calvi C, Montanari P, Galliano I, Bergallo M. · 2026-07-08
unreviewed -
3
Clinicohematological and Genetic Profile of Hereditary Spherocytosis in Children: An Experience From a North Indian Center.
Chakraborty A, Kalra M, Sachdeva A, Kotwal J, Langer S, Saraf A, Rana P, Dahiya S, Arya V, Aggarwal S, Prasad… · 2026-04-23
unreviewed -
4
Persistent Unilateral Scleral Icterus in a Patient with Gilbert Syndrome and Prior Facial Malignancy: A Case Report and Review of the Literature.
Sinha K, Sinha K, Dermarkarian CR. · 2025-11-17
unreviewed -
5
Integrated analysis of UGT1A1 promoter polymorphism, gene expression, and IL-1β reveals genotype-driven susceptibility in Gilbert syndrome.
Hussein SM, Al-Haddad RH, Shareef SA, Abdallah MT. · 2026-06-30
unreviewed - 6
-
7
Prevalence of Steatotic Liver Disease with Fibrosis and Diagnostic Screening Tools in Patients with Psoriasis.
Näslund-Koch C, Løvendorf MB, Løvendorf MB, Martin HM, Johansen MB, Trelle MB, Zachariae C, Gluud LL, Skov L. · 2026-06-15
open access unreviewed - 8
-
9
Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial.
Degaga TS, Pasaribu AP, Tripura R, Ghanchi N, Rajasekhar M, Adhikari B, Ley B, Bamboro SA, Jabbar FA, Hasibua… · 2026-02-11
cited 5× open access unreviewed -
10
Diagnostic Utility of Next-Generation Sequencing for Unconjugated Hyperbilirubinemia in Children.
Kim HJ. · 2026-04-29
open access unreviewed
External claims. These come from an index outside this database and are not checked against it. Treat them as leads.